Anupam Rasayan India Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/lwplxu0smz3f4j9j3cmlg9s8.pdf

Key Takeaways


Order Book & Revenue Visibility

Thakkar: "I think we should be looking at 20%, 25% of growth rate. More sharper number probably I can give you by the end of the second quarter."

Margin Structure & Cost Pass-Through

Thakkar: "if you see our EBITDA margins will be fairly in a consistent band of around 26% to 28%, maybe a little higher probably in a quarter or two, but on an average, you will see that kind of a number."

Technology Moat & Right to Win

Thakkar: "The answer is that we don't take tech-packs from a customer and most of our products and technology is in-house and thanks to our RM team that they have been able to deliver these kinds of products."

Pharma & New Business Development

Thakkar: "Give us a little bit more time to frame that before we come to you and give you a guidance or a more formal view on this because it's right now an MOU, and that will be converted into a more formal relationship as we go forward."

Capex, Returns & Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
FY24 revenue growth20–25% growth rateSharper number by end-Q2 FY24
LOI revenue contributionINR300 crores total in FY24 (INR200 crores addition)FY24
LOI peak revenue~INR1,700 crores annually from INR7,700 crore order bookOver 5–7 years
Long-term revenue CAGR25% plus or minusLong-term basis
EBITDA margin band26–28%, maybe higher in a quarter or twoOngoing
Capex deploymentBalance INR670 crores investedNext 12 months
Net working capitalDrop to sub-INR200 croresOver next few years
New molecule launches10-plus molecules commercializedFY24

Key Metrics

MetricQ1 FY24
Consolidated revenue₹398 cr, +19% YoY
EBITDA margin29%, maintained within long-term band despite deflationary environment
Revenue growth guidance (FY24)20% to 25%, with first half flattish and demand shifting to second half
Order book (LOIs and contracts)₹7,669 cr as of June 30, 2023, providing multi-year revenue visibility
LOIs signed during the quarter₹4,066 cr, including a ₹3,686 cr contract with a Japanese multinational
Life Sciences segment revenue₹255 cr, vs ₹290 cr in Q1 FY23; contributed 90% of total revenue
Other Specialty Chemicals segment revenue₹28 cr, vs ₹14 cr in Q1 FY23
Exports share61% of total revenue
Top 10 customer concentration90% of total revenue, across 24 products
Total commercialized products55, including 2 new fluorinated pharma molecules launched in Q1 FY24
Total customers73, of which 29 are multinationals
Capex spent till end of Q1 FY24₹124.4 cr out of planned ₹670 cr; balance to be invested in next 12 months
Revenue from LOIs and contracts~₹100 cr in FY23, expected to ramp to ~₹300 cr in FY24
ROCE15% in the last year
Net working capital trajectoryDropping from ₹290 cr to ₹250 cr, then to ₹220 cr, to ₹200 cr and sub-₹200 cr over next few years